Astrazeneca PLC (AZN) Releases Earnings Results, Beats Expectations By $0.46 EPS
Astrazeneca PLC (NYSE:AZN) issued its quarterly earnings results on Thursday, July 27th. The company reported $0.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.46, Morningstar.com reports. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The company had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. During the same quarter in the prior year, the business earned $0.83 EPS. Astrazeneca PLC’s revenue was down 9.9% on a year-over-year basis.
Shares of Astrazeneca PLC (NYSE:AZN) traded down 0.56% during trading on Friday, reaching $30.17. The company had a trading volume of 5,189,646 shares. The stock has a market capitalization of $76.39 billion, a PE ratio of 19.79 and a beta of 0.74. The stock’s 50-day moving average price is $33.57 and its 200-day moving average price is $31.37. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60.
The firm also recently declared a None dividend, which will be paid on Monday, September 11th. Stockholders of record on Friday, August 11th will be issued a $0.44 dividend. The ex-dividend date is Wednesday, August 9th. This represents a dividend yield of 2.98%. Astrazeneca PLC’s dividend payout ratio is currently 44.92%.
Several equities research analysts have weighed in on the company. Leerink Swann restated an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Astrazeneca PLC in a report on Wednesday, May 17th. Barclays PLC restated an “overweight” rating on shares of Astrazeneca PLC in a report on Monday, July 3rd. Zacks Investment Research downgraded Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a report on Monday, July 17th. BidaskClub downgraded Astrazeneca PLC from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Finally, Goldman Sachs Group Inc reiterated a “sell” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the stock. Astrazeneca PLC presently has a consensus rating of “Hold” and an average target price of $33.39.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/07/astrazeneca-plc-azn-releases-quarterly-earnings-results-beats-expectations-by-0-46-eps-updated.html.
Hedge funds have recently bought and sold shares of the company. Tompkins Financial Corp raised its stake in shares of Astrazeneca PLC by 67.0% in the first quarter. Tompkins Financial Corp now owns 3,545 shares of the company’s stock worth $100,000 after buying an additional 1,422 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Astrazeneca PLC during the second quarter worth $105,000. Salem Investment Counselors Inc. bought a new stake in shares of Astrazeneca PLC during the first quarter worth $107,000. Tower Research Capital LLC TRC raised its stake in shares of Astrazeneca PLC by 3,782.0% in the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after buying an additional 3,782 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its stake in shares of Astrazeneca PLC by 157.1% in the first quarter. Quadrant Capital Group LLC now owns 4,591 shares of the company’s stock worth $138,000 after buying an additional 2,805 shares in the last quarter. 14.39% of the stock is owned by institutional investors.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.